HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lysophosphatidic acid and apolipoprotein A1 predict increased risk of developing World Trade Center-lung injury: a nested case-control study.

AbstractRATIONALE:
Metabolic syndrome, inflammatory and vascular injury markers measured in serum after World Trade Center (WTC) exposures predict abnormal FEV1. We hypothesized that elevated LPA levels predict FEV₁ < LLN.
METHODS:
Nested case-control study of WTC-exposed firefighters. Cases had FEV₁ < LLN. Controls derived from the baseline cohort. Demographics, pulmonary function, serum lipids, LPA and ApoA1 were measured.
RESULTS:
LPA and ApoA1 levels were higher in cases than controls and predictive of case status. LPA increased the odds by 13% while ApoA1 increased the odds by 29% of an FEV₁ < LLN in a multivariable model.
CONCLUSIONS:
Elevated LPA and ApoA1 are predictive of a significantly increased risk of developing an FEV₁ < LLN.
AuthorsJun Tsukiji, Soo Jung Cho, Ghislaine C Echevarria, Sophia Kwon, Phillip Joseph, Edward J Schenck, Bushra Naveed, David J Prezant, William N Rom, Ann Marie Schmidt, Michael D Weiden, Anna Nolan
JournalBiomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals (Biomarkers) Vol. 19 Issue 2 Pg. 159-65 (Mar 2014) ISSN: 1366-5804 [Electronic] England
PMID24548082 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • APOA1 protein, human
  • Apolipoprotein A-I
  • Biomarkers
  • Lysophospholipids
  • Particulate Matter
  • lysophosphatidic acid
Topics
  • Adult
  • Apolipoprotein A-I (blood)
  • Biomarkers (blood)
  • Case-Control Studies
  • Firefighters
  • Forced Expiratory Volume
  • Humans
  • Lung Injury (blood, etiology, physiopathology)
  • Lysophospholipids (blood)
  • Middle Aged
  • Occupational Exposure
  • Particulate Matter (toxicity)
  • Risk
  • September 11 Terrorist Attacks

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: